Autopsy report · NCT04016363

Impact of the ProbeFix on the Workflow of Pharmacological Stress Echocardiography Examinations

“Industrial partner was not able to provide funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Amir Abbas Mahabadi

Sponsor type

University, hospital or other

Conditions

Coronary Artery Disease

Interventions

ProbeFix; Manual hold

Participants

0

Sites

1

Countries

Germany

Trials that died the same way

• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (73% match in meaning)
• Brain Sleep Deprivation MRI Effects (BEDTIME)
  “Funding was not obtained” (69% match in meaning)
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
  “funding became unavailable” (69% match in meaning)
• Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
  “Funding was not acquired” (67% match in meaning)
• Targeting Leukotrienes in Kidney Disease
  “Funding not available” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.